Harnessing NK Cell Memory for Cancer Immunotherapy

Trends in Immunology

Volumn 37, Issue 12, 2016, Pages 877-888

  Fehniger, Todd A ^a   Cooper, Megan A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; DIFFERENTIATION; HUMAN; MEMORY; NATURAL KILLER CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL DIFFERENTIATION; CYTOMEGALOVIRUS; CYTOTOXICITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; METABOLISM; MOUSE; NEOPLASMS; PROCEDURES; TRANSPLANTATION;

AUTACOID; CANCER VACCINE; CYTOKINE;

ANIMALS; CANCER VACCINES; CELL DIFFERENTIATION; CYTOKINES; CYTOMEGALOVIRUS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; NEOPLASMS;

EID: 84999663822     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.09.005     Document Type: Review

References (69)

1. 1 Yokoyama, W.M., Natural killer cells. Paul, W., (eds.) Fundamental Immunology, 2013, Lippincott Williams & Wilkins, 395–430.
2. 2 Vivier, E., et al. Innate or adaptive immunity? The example of natural killer cells. Science 331 (2011), 44–49.
3. 3 O'Leary, J.G., et al. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat. Immunol. 7 (2006), 507–516.
4. 4 Cooper, M.A., et al. Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 1915–1919.
5. 5 Sun, J.C., et al. Adaptive immune features of natural killer cells. Nature 457 (2009), 557–561.
6. 6 Knorr, D.A., et al. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin. Immunol. 26 (2014), 161–172.
7. 7 Berrien-Elliott, M.M., et al. Improving natural killer cell cancer immunotherapy. Curr. Opin. Organ Transplant. 20 (2015), 671–680.
8. 8 Ruggeri, L., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002), 2097–2100.
9. 9 Cooper, M.A., Yokoyama, W.M., Memory-like responses of natural killer cells. Immunol. Rev. 235 (2010), 297–305.
10. 10 Paust, S., et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat. Immunol. 11 (2010), 1127–1135.
11. 11 Peng, H., et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J. Clin. Invest. 123 (2013), 1444–1456.
12. 12 Paust, S., et al. Adaptive immune responses mediated by natural killer cells. Immunol. Rev. 235 (2010), 286–296.
13. 13 Majewska-Szczepanik, M., et al. Natural killer cell-mediated contact sensitivity develops rapidly and depends on interferon-alpha, interferon-gamma and interleukin-12. Immunology 140 (2013), 98–110.
14. 14 van den Boorn, J.G., et al. Inflammasome-dependent induction of adaptive NK cell memory. Immunity 44 (2016), 1406–1421.
15. 15 Elliott, J.M., Yokoyama, W.M., Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol. 32 (2011), 364–372.
16. 16 Reeves, R.K., et al. Antigen-specific NK cell memory in rhesus macaques. Nat. Immunol. 16 (2015), 927–932.
17. 17 Biron, C.A., et al. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320 (1989), 1731–1735.
18. 18 Kuijpers, T.W., et al. Human NK cells can control CMV infection in the absence of T cells. Blood 112 (2008), 914–915.
19. 19 Dokun, A.O., et al. Specific and nonspecific NK cell activation during virus infection. Nat. Immunol. 2 (2001), 951–956.
20. 20 Smith, H.R., et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 8826–8831.
21. 21 Arase, H., et al. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296 (2002), 1323–1326.
22. 22 Cheng, T.P., et al. Ly49h is necessary for genetic resistance to murine cytomegalovirus. Immunogenetics 60 (2008), 565–573.
23. 23 Sun, J.C., et al. Proinflammatory cytokine signaling required for the generation of natural killer cell memory. J. Exp. Med. 209 (2012), 947–954.
24. 24 Nabekura, T., et al. Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. Immunity 40 (2014), 225–234.
25. 25 O'Sullivan, T.E., et al. Natural killer cell memory. Immunity 43 (2015), 634–645.
26. 26 Beaulieu, A.M., et al. The transcription factor Zbtb32 controls the proliferative burst of virus-specific natural killer cells responding to infection. Nat. Immunol. 15 (2014), 546–553.
27. 27 O'Sullivan, T.E., et al. BNIP3- and BNIP3L-mediated mitophagy promotes the generation of natural killer cell memory. Immunity 43 (2015), 331–342.
28. 28 Min-Oo, G., et al. Proapoptotic Bim regulates antigen-specific NK cell contraction and the generation of the memory NK cell pool after cytomegalovirus infection. J. Exp. Med. 211 (2014), 1289–1296.
29. 29 Guma, M., et al. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104 (2004), 3664–3671.
30. 30 Rolle, A., Brodin, P., Immune adaptation to environmental influence: the case of NK cells and HCMV. Trends Immunol. 37 (2016), 233–243.
31. hi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 14725–14732.
32. + natural killer cells with potent function. Blood 119 (2012), 2665–2674.
33. 33 Malmberg, K.J., et al. Spotlight on NKG2C and the human NK-cell response to CMV infection. Eur. J. Immunol. 42 (2012), 3141–3145.
34. hi natural killer cells. PLoS Pathog., 10, 2014, e1004441.
35. 35 Schlums, H., et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42 (2015), 443–456.
36. 36 Lee, J., et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42 (2015), 431–442.
37. 37 Hwang, I., et al. Identification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functions. Int. Immunol. 24 (2012), 793–802.
38. 38 Zhang, T., et al. Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRγ deficiency. J. Immunol. 190 (2013), 1402–1406.
39. −/− umbilical cord blood. J. Immunol. 192 (2014), 1471–1479.
40. 40 Liu, L.L., et al. Critical role of CD2 co-stimulation in adaptive natural killer cell responses revealed in NKG2C-deficient humans. Cell Rep. 15 (2016), 1088–1099.
41. 41 Keppel, M.P., et al. Murine NK cell intrinsic cytokine-induced memory-like responses are maintained following homeostatic proliferation. J. Immunol. 190 (2013), 4754–4762.
42. 42 Romee, R., et al. Cytokine activation induces human memory-like NK cells. Blood 120 (2012), 4751–4760.
43. 43 Leong, J.W., et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol. Blood Marrow Transplant. 20 (2014), 463–473.
44. + NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia 30 (2016), 456–463.
45. + NK cells in healthy humans. Clin. Exp. Immunol. 185 (2016), 239–251.
46. 46 Elmaagacli, A.H., et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118 (2011), 1402–1412.
47. 47 Ito, S., et al. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant. 48 (2013), 1313–1316.
48. 48 Green, M.L., et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122 (2013), 1316–1324.
49. 49 Björklund, A.T., et al. Naive donor NK cell repertoires associated with less leukemia relapse after allogeneic hematopoietic stem cell transplantation. J. Immunol. 196 (2016), 1400–1411.
50. 50 Ni, J., et al. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J. Exp. Med. 209 (2012), 2351–2365.
51. + T cell help. Oncoimmunology, 2016, 10.1080/2162402X.2016.1219009 Published online August 5, 2016.
52. 52 Romee, R., et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci. Transl. Med., 8, 2016, 357ra123.
53. 53 Wagner, J.A., et al. Mechanisms governing human memory-like natural killer cell function. Immunology 2016, AAI Annual Meeting, May 13–17, American Association of Immunologists, 2016.
54. 54 Bachanova, V., et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123 (2014), 3855–3863.
55. 55 Curti, A., et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118 (2011), 3273–3279.
56. + tumor cells. mAbs 6 (2014), 728–739.
57. + targets. Blood 123 (2014), 3016–3026.
58. 58 Rothe, A., et al. A Phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125 (2015), 4024–4031.
59. 59 Schmohl, J.U., et al. Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol. Ther. 24 (2016), 1312–1322.
60. 60 Chu, J., et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28 (2014), 917–927.
61. 61 Hermanson, D.L., Kaufman, D.S., Utilizing chimeric antigen receptors to direct natural killer cell activity. Front. Immunol., 6, 2015, 195.
62. 62 Sarhan, D., et al. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Res., 2016, 10.1158/0008-5472.CAN-16-0839 Published online August 8, 2016.
63. 63 Koka, R., et al. Interleukin (IL)-15Rα-deficient natural killer cells survive in normal but not IL-15Rα-deficient mice. J. Exp. Med. 197 (2003), 977–984.
64. 64 Jamieson, A.M., et al. Turnover and proliferation of NK cells in steady state and lymphopenic conditions. J. Immunol. 172 (2004), 864–870.
65. 65 Waldmann, T.A., The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol. Res. 3 (2015), 219–227.
66. 66 Romee, R., et al. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo), 2014, 2014, 205796.
67. 67 Björkstrom, N.K., et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J. Exp. Med. 208 (2011), 13–21.
68. 68 Petitdemange, C., et al. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog., 7, 2011, e1002268.
69. 69 Min-Oo, G., Lanier, L.L., Cytomegalovirus generates long-lived antigen-specific NK cells with diminished bystander activation to heterologous infection. J. Exp. Med. 211 (2014), 2669–2680.